Google
ORKA — ORUKA THERAPEUTICS, INC. (Healthcare >> Biotechnology)
ORKA FAQ
What is ORKA's ROE?
ORUKA THERAPEUTICS, INC. reports a Return on Equity (ROE) of -23.89%.
What is ORKA's dividend yield?
ORUKA THERAPEUTICS, INC. offers a dividend yield of 0.00%.
What is ORKA's Deepscope Quality Score?
Deepscope rates ORKA's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ORKA?
Deepscope's AI Timing Score for ORKA is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ORKA belong to?
ORUKA THERAPEUTICS, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 60.14
Price
-2.14
(-3.44%)
Day Change
|
|
|---|
ORKA, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 60.14 |
| PBV / Sector |
7.09 / 4.63
|
| Earning Per Share | -2.03 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
70.47 M
|
| Average 1W Daily Value |
68.13 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
37% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:06 |
| Symbol | ORKA |
| Name | ORUKA THERAPEUTICS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 60.31 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,449.85 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 855 Oak Grove Avenue, Menlo Park, CA, United States, 94025
Phone: 650 606 7910
Website: https://orukatx.com
Employees: 68
Sector: Healthcare >> Biotechnology
Description: Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
